Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes. - Wikidata - wikimedia - TriplyDB

Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes.

Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes.

http://www.wikidata.org/entity/Q36474572

about

Epigenetics of colorectal cancer A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers Beyond hypomethylating agents failure in patients with myelodysplastic syndromes New strategies in myelodysplastic syndromes: application of molecular diagnostics to clinical practice Epigenome-based personalized medicine in human cancer Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends.Established and emerging targeted therapies in the myelodysplastic syndromes.Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocol.Simultaneous Manifestation of Chronic Myelomonocytic Leukemia and Multiple Myeloma during Treatment by Prednisolone and Eltrombopag for Immune-Mediated Thrombocytopenic Purpura.Current therapy of myelodysplastic syndromes There's risk, and then there's risk: The latest clinical prognostic risk stratification models in myelodysplastic syndromes.Combination of azacitidine and lenalidomide in myelodysplastic syndromes or acute myeloid leukemia-a wise liaison?Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia.Clinical development of demethylating agents in hematology Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IP Expanding role of lenalidomide in hematologic malignancies Concise drug review: azacitidine and decitabine Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis.Hypomethylating agents after allogeneic blood stem cell transplantation.Review of therapeutic options and the management of patients with myelodysplastic syndromes.5-Azacytidine for the treatment of myelodysplastic syndromes.Dendritic cells in myelodysplastic syndromes: from pathogenesis to immunotherapy.Higher-risk myelodysplastic syndromes with del(5q): is sequential azacitidine-lenalidomide combination the way to go?Novel therapeutic strategies using hypomethylating agents in the treatment of myelodysplastic syndrome.Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide.Deacetylase inhibitors for the treatment of myelodysplastic syndromes.Update on the pharmacotherapy for myelodysplastic syndromes.Hematopoietic Cell Transplantation for Older Patients with MDS.Epigenetic Therapy in Acute Myeloid Leukemia: Current and Future Directions.Outlook and Management of Patients with Myelodysplastic Syndromes Failed by Hypomethylating Agents.The clinical use of DNA methyltransferase inhibitors in myelodysplastic syndromes.Unraveling Myelodysplastic Syndromes: Current Knowledge and Future Directions.Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications.Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings.DNA Hypomethylating Drugs in Cancer Therapy.Safety and efficacy of azacitidine in elderly patients with intermediate to high-risk myelodysplastic syndromes.A phase 2 trial of high dose lenalidomide in patients with relapsed/refractory higher-risk myelodysplastic syndromes and acute myeloid leukaemia with trilineage dysplasia.Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome.

P2860

Q24598045-B44427F1-3EE3-416E-8F5B-3525F52F6490 Q26743743-B7EA1BE8-1896-4A87-91B1-0BF7F0CCE30C Q26827079-655CD477-A707-4642-BF43-B62A977C5193 Q27016511-36D97647-A046-401D-B601-BA213AC9F73D Q28083951-B38EEA56-1472-4039-BCAC-3B3A1FE52FAC Q30235355-B555B05C-2783-4385-96A3-34C9388C584A Q30245476-BF278566-62DA-4746-B183-EF48D030B778 Q33434768-5B663B0F-7783-4042-A791-328496EC665E Q33435162-EBE7961A-2C82-4AC7-A1BB-B32D01DF42D6 Q34013796-977F9A14-55F1-4C72-971A-2992F622806E Q34049017-119B2B7E-D92A-4FEF-9F4B-B96DA7DF2E4C Q34342944-D5535872-BFF9-41EB-94EC-B5D71AB1B918 Q34350209-8DFA9F49-E262-4309-8DEC-75F116E1DF3F Q34395179-9F461C7F-4BD6-4190-9D00-EE7DD895AD64 Q34783754-A66AB91B-C11E-452D-B538-AB877655546A Q34986462-92DBC04C-DBB2-45E8-B281-B86C708B476B Q35592305-D4971A24-FD27-45B3-B001-CA09C3CE5968 Q36871721-B4735675-B041-417B-80E4-5250E488FAB3 Q37074311-889C14C2-1919-44C3-950C-EC50EF840384 Q37216367-A869C3A2-9428-4688-88DD-AD854513D13D Q37531039-591CB59B-FF7B-4081-9462-F7C8AB3FC1DC Q38095121-8A6451A0-80A4-473F-AF80-34B457285E67 Q38102062-3942D41D-C7E8-4950-98C7-1BAF03A9CCA0 Q38110935-0267B9DC-D5BF-4D28-8329-F6249824E074 Q38115584-0F44CA75-3EC7-475C-8691-2CA84FBB6184 Q38172875-EC846BF2-F51B-49D0-86C6-40E582A54C58 Q38195796-902044F9-4B40-4657-8CB3-D6582D75E43F Q38233492-CEF2AE34-6C3F-4F99-B6A3-D3DE448B434B Q38235662-FCB85A60-6246-4F9F-BB45-F5C85A341144 Q38252578-07BCFCF2-83A5-407C-B3BA-ADD4F699C734 Q38537883-5B032735-5BF3-4F45-AE27-89A23ADE16EC Q38540859-65AE44C3-778A-4E2F-A6FA-63F4186ECEEE Q38570399-DFB5977C-C4C5-4E01-A70F-0F8C8F36D6C6 Q38678113-DCBD23FE-BDC5-4B2C-860A-D2217B0AA2DC Q38758162-34F64DA7-579E-4E56-9F01-99DC8668BD80 Q38961023-E4F579B9-B17E-402E-AA6D-C2376F0D4CAA Q38979940-4330DEF3-A434-4C6E-9EE8-744A31B705EA Q39064474-1F5DA09D-62CA-47C8-9A1F-D3D27708B279 Q39240258-98A714D4-0B4C-4419-B831-56904D5563FF Q40139200-3A75687B-511B-4A40-818A-B6772C181EE4

P2860

Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes.

http://www.wikidata.org/entity/Q36474572

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Phase 2 study of the lenalidom ...... isk myelodysplastic syndromes.

@ast

Phase 2 study of the lenalidom ...... isk myelodysplastic syndromes.

@en

type

label

Phase 2 study of the lenalidom ...... isk myelodysplastic syndromes.

@ast

Phase 2 study of the lenalidom ...... isk myelodysplastic syndromes.

@en

prefLabel

Phase 2 study of the lenalidom ...... isk myelodysplastic syndromes.

@ast

Phase 2 study of the lenalidom ...... isk myelodysplastic syndromes.

@en

P1433

Q36474572-EE4AB9B9-48F5-467D-961F-B993CEDE2E7C

P1476

Q36474572-F35B8007-CD4F-432B-8E11-A7B49F1CF77E

P2093

Q36474572-097BFC29-3270-4417-9616-F691BD950688

Q36474572-099F9C1B-30E4-4C11-AE67-632BEE5A7DF0

Q36474572-1D2BCB68-2A9F-4BBD-BD2D-00EB2BB03280

Q36474572-215B01A2-37B3-46C8-AE71-1E117697BB1A

Q36474572-2EE15B61-660D-449E-80F9-98740AF56640

Q36474572-339C757A-4FA3-47F5-9A02-25621EA10F4E

Q36474572-41C2E479-1E54-4E0B-A90F-60FAD851D246

Q36474572-48FD2DE1-C33F-4486-9F2B-8E9D4F6FB0C3

Q36474572-4EDA3437-0CB1-48FC-9E87-D377A0C1CE96

Q36474572-4EF1019B-263C-4E54-92A3-61F06B11DBD1

P2860

Q36474572-173252A6-63C4-4114-AD88-76C64B8E69D1

Q36474572-22E1E68D-A83B-4BCD-9A95-7FCFE0D899FC

Q36474572-24CC7E31-6B99-4A18-A055-8992C6D7C86A

Q36474572-25CC02A1-E62C-4B2E-BD7C-540B1368A9C9

Q36474572-280D73EF-AD81-4288-8A42-25E7BF3EB534

Q36474572-2815D3CC-A4F4-48E6-A92E-F389D1C6BD6E

Q36474572-2AE5B6A7-1B21-46A2-8FA9-04076B88D81D

Q36474572-2F9F99BA-F256-4AF5-A773-EA66D6677DF7

Q36474572-347383A1-8C12-49FA-8C9A-69861764F566

Q36474572-47B706BA-322B-4524-8A2F-6D6D8A95A52B

P304

Q36474572-8C5C35E3-DB2F-43E1-9E57-D1EFC4CD48C1

P31

Q36474572-492A3D1F-293F-42BD-A0DA-BBE004EF550F

P356

Q36474572-EC2EE5EC-DF78-46EA-A621-A3D54FFB3A34

P407

Q36474572-91A11C57-08FF-4703-A94C-344A6D4F63B9

P433

Q36474572-DD373FF2-F149-40E0-A8A9-1818AA9DC33E

P478

Q36474572-94EDC9D1-E9E3-47F9-B68B-FB395430F3F8

P577

Q36474572-367C0077-7A9D-476A-A628-4758AAEF76E0

P5875

Q36474572-0A6CF7FC-BED2-4201-A313-DA7254E4A602

P698

Q36474572-C84BF18F-4B50-4376-8044-1CC0D9CD4722

P932

Q36474572-52C1BC86-D6B2-4A3E-BDF0-CB77FBCDE2EB

P356

BLOOD-2012-06-434639

P1433

P1476

Phase 2 study of the lenalidom ...... isk myelodysplastic syndromes.

@en

P2093

Alan F List

http://www.w3.org/2001/XMLSchema#string

Ali Tabarroki

http://www.w3.org/2001/XMLSchema#string

Andres Jerez

http://www.w3.org/2001/XMLSchema#string

Anjali S Advani

http://www.w3.org/2001/XMLSchema#string

David Cuthbertson

http://www.w3.org/2001/XMLSchema#string

Hideki Makishima

http://www.w3.org/2001/XMLSchema#string

Jaroslaw P Maciejewski

http://www.w3.org/2001/XMLSchema#string

Jeffrey Lancet

http://www.w3.org/2001/XMLSchema#string

Jennifer Paleveda

http://www.w3.org/2001/XMLSchema#string

Joyce Juersivich

http://www.w3.org/2001/XMLSchema#string

P2860

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

Identification of RPS14 as a 5q- syndrome gene by RNA interference screen

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML

The World Health Organization (WHO) classification of the myeloid neoplasms

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

International scoring system for evaluating prognosis in myelodysplastic syndromes

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

Efficacy of lenalidomide in myelodysplastic syndromes.

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

P304

4945-4951

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2012-06-434639

http://www.w3.org/2001/XMLSchema#string

P407

P433

25

http://www.w3.org/2001/XMLSchema#string

P478

120

http://www.w3.org/2001/XMLSchema#string

P577

2012-08-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230723974

http://www.w3.org/2001/XMLSchema#string

P698

22915641

http://www.w3.org/2001/XMLSchema#string

P932

3525020

http://www.w3.org/2001/XMLSchema#string